a Objective: Perforin is an important component of the death machinery of cytotoxic T cells (CTL). To evaluate functional differences between HIV-and cytomegalovirus (CMV)-specific CTL of coinfected patients, the frequencies of the respective perforinexpressing T cells were analysed in a rapid whole blood assay.
The fraction of perforin-expressing HIV-specific CD8 T cells is a marker for disease progression in HIV infection Tanja To evaluate functional differences between HIV-and cytomegalovirus (CMV)-specific CTL of coinfected patients, the frequencies of the respective perforinexpressing T cells were analysed in a rapid whole blood assay.
Introduction CD8-positive cytotoxic T cells (CTL) play a central role in the defence against viral infections. In HIV infection, CTL contribute to the control of the viremia, both during the primary infection and subsequently in the persistent phase [1, 2] . A potent CTL response is a predictor of lower viral load and prolonged survival; however, it rarely results in HIV eradication [3] [4] [5] . Likewise, virus-specific CTL in cytomegalovirus (CMV) infection fail to eliminate CMV from the host but restrict its replication to below pathogenic levels [6] .
One of the key components of the death machinery of CTL is perforin. This protein is involved in the formation of pores within target cells, thereby providing intracellular entry to other components of the lytic granules, such as granzyme A, granzyme B and granulysin [7, 8] . The function of perforin was best demonstrated in mice lacking perforin expression. They had a severe dysfunction in CTL activity and, consequently, were unable to clear infection with the non-cytopathic lymphocytic choriomeningitis virus [9, 10] . Furthermore, using this infection model or a graft-versus-host disease model it can be shown that cytotoxicity mediated by CD8 T cells in vivo is nearly completely dependent on the perforin/granzyme system [9] [10] [11] .
The expression of perforin and granzymes may be used as diagnostic markers for activated cytotoxic cells in vivo [12] . Upon antigen-specific stimulation of CD8 T cells, the synthesis of perforin and the formation of lytic granules are detectable after 24 to 48 hours. Restimulation of cells via their antigen receptors simultaneously leads to rapid degranulation and new synthesis of lytic proteins [7] . As a consequence, the cytolytic activity is constitutively maintained, which contrasts with the rapid on/off cycling of cytokine expression [13] . Therefore, measurement of both perforin and intracellular cytokines provides a method of determining the antigen specificity of effector cells ex vivo.
To investigate the characteristics of virus-specific CD8 T cells of patients coinfected with HIV and CMV, the frequencies of perforin and interferon-ª coexpressing T cells were measured in a rapid whole-blood assay. Stimulation of antigen-specific CD4 and CD8 T cells within whole blood The recombinant HIV-1Lai Pr55 gag virus-like particles (VLP) were produced in a baculovirus expression system as described previously [14] . Antigen stimulation of HIV-and CMV-specific CD8 T cells was performed in whole blood as described [15, 16] .
Methods Subjects

Statistical analysis
Statistical analysis was performed using the Prism V3.00 Software (Graphpad, San Diego, California, USA). Significant differences were determined using the Mann-Whitney test and the Kruskall-Wallis test for comparison of two or more unpaired groups, respectively, and the Wilcoxon signed rank test for a paired analysis of the HIV-and CMV-specific stimulation within the same individual. The Spearman's nonparametric correlation test was used to analyse the association between the fraction of perforin-expressing HIV-specific CD8 T cells and CD4 T cell counts.
Results
The frequency of HIV-and CMV-specific CD8 T can be directly quantified from whole blood by intracellular interferon-ª staining. As antigens, virus-like gag-particles (Pr55 gag VLP) and complete CMV antigen have been used for HIV-1 and CMV, respectively [15, 16] . Both antigens were simply added to whole blood, where they entered the HLA class I pathway of antigen presentation, thus allowing measurement of specific antiviral CD8 T cell responses against complete virus proteins without the need for HLA typing or epitope characterization [15, 16] . By combining CD8, interferon-ª and perforin staining after antigen-specific stimulation, the frequency of effector CD8 T cells was analysed in individuals coinfected with HIV and CMV. Stimulation with control antigens did not change the absolute number of perforin-expressing CD8 T cells, demonstrating that these effector cells pre-existed and were not induced during the assay (data not shown). To demonstrate that perforin detection is not significantly diminished upon effector cell engagement, whole blood was incubated with phytohaemagglutinin, which is known to induce cellular cytotoxicity nonspecifically [17, 18] . While a slight reduction in the mean fluorescence intensity of perforin expression is visible, no reduction in the total frequency of perforinexpressing CD8 T cells was observed, indicating that a reliable frequency determination is possible (data not shown).
Antigen-specific perforin-expressing CD8 T cells in antiretroviral treatment or immunosuppression The fraction of perforin-expressing T cells among the virus-specific CD8 T cells is a measure for relative CTL effector frequencies in peripheral blood. Before evaluating potential differences between virus-specific cells within double-infected individuals, this fraction was determined in cohorts of HIV-seropositive subjects with and without antiviral treatment, and in CMVseropositive renal transplant recipients and healthy controls. A wide range of frequencies of perforinpositive HIV-specific CD8 T cells was observed; however the median was not significantly different in treated and non-treated individuals (Fig. 1a) . There was a successive trend towards a lower fraction of perforinexpressing CMV-specific CD8 T cells from healthy controls to renal transplant recipients and HIV-infected individuals; however, this also was not significant (Fig.  1b) . Together these findings indicate that, on average, perforin expression is a rather stable marker for effector cells and is relatively insensitive to antiviral treatment and immunosuppression.
Perforin-expressing HIV-specific and CMVspecific CD8 T cells in double infection Within a single patient, the fraction of perforin-expressing HIV-specific CD8 T cells in peripheral blood was lower than the fraction among the CMV-specific CD8 T cells (Fig. 2a) . Virus-specific effector T cell frequencies were analysed in 15 HIV and CMV double-infected individuals. While overall the fraction of perforin-expressing CD8 T cells varied widely from 0 to 95%, in 13 of 15 individuals, the fraction was lower for HIV-specific than for CMV-specific cells. This difference ranged from 1.1-to over 10-fold (P ¼ 0.0009 by non-parametric Wilcoxon signed rank test for paired values). No obvious common features could be identified for the two individuals who did not follow this trend.
Perforin-expressing HIV-specific CD8 T cells as a surrogate marker for disease progression The frequency of perforin-expressing HIV-specific CD8 T cells inversely correlated with the CD4 T cell count (Fig. 2b) . The number of patients positive for HIV and CMV did not cover the whole range of CD4 T cell counts and, therefore, no correlation between the CD4 T cell count and the perforin-expressing CMV-specific CD8 T cells was recognized. To identify clinically significant correlations with the perforin-expressing HIV-specific CD8 T cells, the relation to classical parameters of HIV infection such as virus load, virus-specific and virus-non-specific CD4 T cell counts and antiviral treatment was analysed. Only the relation with the absolute CD4 T cell count was statistically significant (r ¼ 0.52; P ¼ 0.0020). The cohort included both treated and untreated patients, the latter covering only part of the CD4 T cell range. Antiviral treatment affects that cell population. However, 10 of the 22 treated patients had a comparable CD4 T cell count at the day of analysis as found before starting treatment. If only these patients were considered, a similar significant correlation was observed. Likewise, if only the 10 untreated normal progressors were analysed, the respective correlation was robust (r ¼ 0.74; P ¼ 0.0154; Fig.  2b ).
Discussion
The fraction of perforin-expressing HIV-specific CD8 T cells inversely correlated with the peripheral blood CD4 T cell count, thus providing another surrogate marker for disease progression (Fig. 2b) . Perforin is expressed in antigen-primed CD8 T cells with a cytolytic potential and might, therefore, be considered as an activation marker. However, in contrast to other markers of activation such as CD25, CD38, CD69, HLA-DR or cytokine production, perforin is not rapidly cycling [13, 19] . This might explain the relative insensitivity towards immunosuppression and antiviral treatment (Fig. 1) , the latter being responsible for the reduction in the total frequency of HIV-specific CD4 and CD8 T cells [15] . Nevertheless, the observed correlation is comparable with that of other more dynamic activation markers such as CD38, HLA-DR or Ki67, which are also inversely related to CD4 T cell counts [19, 20] .
Within double-infected individuals, the fraction of perforin-expressing HIV-specific CD8 T cells in peripheral blood was significantly lower than the fraction of the perforin-expressing CMV-specific CD8 T cells (Fig. 2a) . This difference does not seem to be a result of selective engagement of HIV-specific effector cells because (i) antiviral treatment, while reducing the HIV load, had no significant effect on the effector cell fraction and (ii) experimentally induced effector cell engagement did not influence the frequency determination of perforin expression. Therefore, this lower fraction observed suggests a selective process presumably driven by T cell receptor signalling. In this context, it is noteworthy that antigen selectivity was recently described in connection with various virusrelated CD8 T cell dysfunctions [21] . Mechanistically, different threshold-dependent processes like antigenspecific helper T cell levels or antigen dose could be involved but this has yet to be determined.
The above observations are in line with recent studies hypothesizing that HIV-specific CD8 T cells have a dysfunction in their cytolytic properties [22] . This hypothesis is based on several observations: the reduced frequency of perforin-expressing cells relative to another persistent pathogen ( [23, 24] and this study), a reduced cytolytic potential [24] , their immature phenotype [24, 25] and their reduced capacity to interact with endothelial cells [26] . However, in most cases, these parameters were assessed for peripheral blood leukocytes and might not, therefore, reflect the immunologically active compartments in which HIV replication is prominent. Indeed, colocalization of replicating HIV and cytotoxic effector T cells was recently demonstrated in splenic white pulp and germinal centres of tonsils from HIV-seropositive patients [27] . While no direct comparison of the cytolytic capacity of CD8 T cells with other antigen specificity was performed, these findings suggest the importance of the location for which an analysis is performed. Only when location is taken into account can differences resulting from priming and trafficking to or from replication sites be excluded.
